Little is known about the humoral immune response against DNA prime-recombinant adenovirus 5 (rAd5) boost HIV vaccine among HIV-infected patients on long-term suppressive antiretroviral therapy (ART). Previous studies emphasized cellular immune responses; however, current research suggests both cellular and humoral responses are likely required for a successful therapeutic vaccine. Thus, we aim...

shigella species (spp.) are gram-negative bacteria that are responsible for shigellosis. although it can be controlled via antibiotics, increasing number of antibiotic resistant isolates of shigella have been reported. therefore, other strategies such as production of specific vaccine against this organism could be a suitable therapeutic approach. attenuated live vaccines produced by gene delet...

Generation of a therapeutic immune response against a diverse set of antigens expressed by a patient’s cancer is a central goal of cancer immunotherapy. This goal is important because diverse responses may prevent escape of antigen loss variants. To accomplish this goal we have developed tumor-derived autophagosome-enriched vaccines, “DRibbles”, that sequester a complex mixture of proteins incl...

PSA-TRICOM (PROSTVAC) is a novel vector-based vaccine designed to generate a robust immune response against prostate-specific antigen (PSA)-expressing tumor cells. The purpose of this report is to present an overview of both published studies and new data in the evaluation of immune responses to the PSA-TRICOM vaccine platform, currently in phase III testing. Of 104 patients tested for T-cell r...

the development of a therapeutic vaccine against human papillomavirus (hpv) is important for the control of cervical cancer. e7 is the major transforming protein produced in cervical cancers, and therefore represents potential tumor-specific antigen that could be the target of immunotherapy for cervical cancer. among different vaccine strategies, protein-based vaccines are capable of generating...

Chronic hepatitis B is still a major public health issue despite the successful prophylactic vaccination attempts. Chronicity of hepatitis B virus(HBV) is mainly due to its ability to debilitate host's immune system. Therefore, major measures have been taken to stop this process and help patients with chronic hepatitis B infection recover from their illness. While satisfactory results have been...

UNLABELLED Most blinding ocular herpetic disease is due to reactivation of herpes simplex virus 1 (HSV-1) from latency rather than to primary acute infection. No herpes simplex vaccine is currently available for use in humans. In this study, we used the HLA-A*02:01 transgenic (HLA Tg) rabbit model of ocular herpes to assess the efficacy of a therapeutic vaccine based on HSV-1 gD epitopes that a...

Abstract The viral E6 and E7 oncoproteins of human papillomavirus (HPV) are strongly associated with cervical cancer. We developed assessed the efficacy an mRNA-HPV therapeutic vaccine (mHTV), containing proteins, in C57BL/J mice. mHTV generated robust T cell-mediated immune responses induced short-lived effector tetramer-specific cells. immunization significantly suppressed tumor growth mice i...

Hepatitis C virus (HCV) is known to cause hepatitis and hepatocellular carcinoma. E2 envelope glycoprotein of HCV type (HCV-E2) has been reported to bind human host cells and is a major target for developing anti-HCV vaccines. However, the therapeutic vaccine for infected patients still needs further development. The vaccine aims to provide cytotoxic T-cells to eliminate infected cells and hepa...

Cervical cancer is caused by persistent high-risk type of human papillomavirus (HPV) infection. especially types 16 and 18. The choice cervical therapy associated with many side effects, tumor drug resistance, high costs. A more efficient, safe effective needed, such as therapeutic vaccine which targets host factors related to E6 E7 HPV oncoprotein. oncoprotein inhibits p53, whereas pRb. Therap...